Physician profile
Randy B Carter
NPI 1174569990
$1,489.71
in general payments reported to CMS, 2019-2025
16 companies · $294 in 2025
The $294 reported for 2025 was more than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $150 · 2020: $160 · 2021: $179 · 2022: $268 · 2023: $102 · 2024: $336 · 2025: $294.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $733.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $732.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $396.95 | 2022-2025 | Miebo, Xiidra, Infuse |
| Allergan, INC. | $227.56 | 2019-2021 | |
| Dompe US, INC. | $190.74 | 2019-2024 | Oxervate |
| Alcon Vision LLC | $173.83 | 2021-2025 | Clareon |
| Abbvie INC. | $89.98 | 2023-2024 | Vuity, Lumigan |
| Biotissue Holdings INC. | $79.11 | 2024 | |
| Johnson & Johnson Vision Care, INC. | $68.63 | 2019-2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $60.71 | 2019-2021 | |
| Coopervision INC. | $53.72 | 2020-2021 | |
| Hoffmann-La Roche Limited | $46.20 | 2019 | |
| Tarsus Pharmaceuticals, INC. | $32.88 | 2025 | Xdemvy |
| Sun Pharmaceutical Industries INC. | $19.17 | 2022 | |
| Novartis Pharmaceuticals Corporation | $17.77 | 2022 | |
| Sight Sciences, INC. | $17.38 | 2023 | Tearcare System |
| Kala Pharmaceuticals, INC. | $15.08 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Randy Carter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.